AI Engines For more Details: Perplexity Kagi Labs You
Antifungal Action: Terconazole belongs to the azole class of antifungal drugs. It works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. By disrupting the integrity of the fungal cell membrane, terconazole effectively kills or inhibits the growth of Candida species, thereby treating vaginal yeast infections.
Treatment of Vaginal Candidiasis: Terconazole is available as vaginal suppositories, creams, or ointments for the treatment of vaginal yeast infections. It is inserted into the vagina using an applicator and typically used for a specified duration as directed by a healthcare provider.
Symptom Relief: Terconazole relieves symptoms associated with vaginal yeast infections, including itching, burning, irritation, and abnormal vaginal discharge. It helps restore the natural balance of microorganisms in the vagina by eliminating excessive fungal growth.
Dosage Forms: Terconazole is available in different strengths and formulations, including 0.4% and 0.8% vaginal creams or suppositories. The choice of strength and formulation depends on the severity of the infection and healthcare provider's recommendations.
Side Effects: Common side effects of terconazole may include vaginal irritation, itching, burning, or discomfort at the application site. These side effects are usually mild and temporary. However, if irritation persists or worsens, patients should consult their healthcare provider.
Allergic Reactions: In rare cases, some individuals may experience allergic reactions to terconazole, characterized by symptoms such as rash, hives, swelling, or difficulty breathing. Patients should seek immediate medical attention if they experience any signs of an allergic reaction after using terconazole.
Drug Interactions: There are limited reports of significant drug interactions with terconazole. However, patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to prevent potential interactions.
Pregnancy and Lactation: Terconazole is generally considered safe to use during pregnancy, but pregnant women should consult their healthcare providers before using any medication. Similarly, breastfeeding women should seek medical advice before using terconazole to ensure the safety of the infant.
Effectiveness: Terconazole is highly effective in treating vaginal yeast infections caused by Candida albicans. However, if symptoms persist or worsen after completing the prescribed course of treatment, patients should consult their healthcare provider for further evaluation and management.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0 | 0 | |
| ADHD | 1.8 | 0.2 | 8 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.4 | 0.1 | 3 |
| Allergies | 0.9 | 1.2 | -0.33 |
| Allergy to milk products | 0.4 | 0 | 0 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 1 | 3.8 | -2.8 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.1 | 12 |
| Ankylosing spondylitis | 1 | 0.8 | 0.25 |
| Anorexia Nervosa | 1.4 | -1.4 | |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 0 | 0.7 | 0 |
| Atherosclerosis | 0.3 | 0.6 | -1 |
| Atrial fibrillation | 1.2 | 1.2 | 0 |
| Autism | 2.3 | 3.9 | -0.7 |
| Bipolar Disorder | 0.4 | 0.8 | -1 |
| Brain Trauma | 0.1 | 0.7 | -6 |
| Carcinoma | 0.6 | 0.6 | 0 |
| Celiac Disease | 0.3 | 0.8 | -1.67 |
| Cerebral Palsy | 0 | 0.9 | 0 |
| Chronic Fatigue Syndrome | 1.4 | 1.1 | 0.27 |
| Chronic Kidney Disease | 0.4 | 1.6 | -3 |
| Chronic Lyme | 0.7 | -0.7 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | -0.9 | |
| Chronic Urticaria (Hives) | 1.4 | -1.4 | |
| Coagulation / Micro clot triggering bacteria | 0.6 | -0.6 | |
| Colorectal Cancer | 1.5 | 0.5 | 2 |
| Constipation | 0.4 | 0.5 | -0.25 |
| Coronary artery disease | 0.7 | 0.3 | 1.33 |
| COVID-19 | 2.2 | 5.3 | -1.41 |
| Crohn's Disease | 2.4 | 3.1 | -0.29 |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.6 | -0.6 | |
| Depression | 2.4 | 2.9 | -0.21 |
| Dermatomyositis | 0 | 0 | |
| Eczema | 0.2 | 0.6 | -2 |
| Endometriosis | 0.5 | 0.4 | 0.25 |
| Epilepsy | 1 | 0.3 | 2.33 |
| Fibromyalgia | 0.5 | 1.9 | -2.8 |
| Functional constipation / chronic idiopathic constipation | 1.6 | 2.4 | -0.5 |
| gallstone disease (gsd) | 0.2 | 0.5 | -1.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.1 | 5 |
| Generalized anxiety disorder | 0.2 | 0.6 | -2 |
| Gout | 0.2 | -0.2 | |
| Graves' disease | 0.4 | 0.6 | -0.5 |
| Halitosis | 0.2 | 0.2 | |
| Hashimoto's thyroiditis | 0.8 | 0.3 | 1.67 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.3 | 0.5 | 1.6 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 0.3 | -0.3 | |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | 0 |
| hypersomnia | 0 | 0 | |
| hypertension (High Blood Pressure | 0.5 | 2.6 | -4.2 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 2.8 | -2.8 | |
| Inflammatory Bowel Disease | 1.1 | 4.3 | -2.91 |
| Insomnia | 0.3 | 0.9 | -2 |
| Intelligence | 0.6 | 0.9 | -0.5 |
| Intracranial aneurysms | 0.4 | 0.1 | 3 |
| Irritable Bowel Syndrome | 1.5 | 1.6 | -0.07 |
| Liver Cirrhosis | 1.2 | 1.1 | 0.09 |
| Long COVID | 2.2 | 3.4 | -0.55 |
| Low bone mineral density | 0.9 | -0.9 | |
| Lung Cancer | 0.2 | -0.2 | |
| ME/CFS with IBS | 0.8 | -0.8 | |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| Menopause | 0.4 | 0.4 | |
| Metabolic Syndrome | 2.2 | 3.2 | -0.45 |
| Mood Disorders | 2.8 | 2.9 | -0.04 |
| multiple chemical sensitivity [MCS] | 0 | 0 | |
| Multiple Sclerosis | 0.3 | 3.3 | -10 |
| Multiple system atrophy (MSA) | 0.9 | 0.2 | 3.5 |
| Neuropathy (all types) | 0 | 0 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 1.8 | -0.8 |
| NonCeliac Gluten Sensitivity | 0 | 0 | |
| Obesity | 2.6 | 0.8 | 2.25 |
| obsessive-compulsive disorder | 2 | 2 | 0 |
| Osteoarthritis | 0.4 | 0.1 | 3 |
| Osteoporosis | 0.4 | 0.3 | 0.33 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.3 | 1.9 | -5.33 |
| Polycystic ovary syndrome | 0.4 | 0.9 | -1.25 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.2 | 0.2 | |
| primary biliary cholangitis | 0.4 | -0.4 | |
| Psoriasis | 0.9 | 1.8 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.6 | 1.7 | 0.53 |
| Rosacea | 0.2 | 0.5 | -1.5 |
| Schizophrenia | 1.4 | 0.9 | 0.56 |
| scoliosis | 0.2 | 0.5 | -1.5 |
| Sjögren syndrome | 1 | 1 | 0 |
| Sleep Apnea | 0.4 | 1 | -1.5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | -0.1 | |
| Stress / posttraumatic stress disorder | 0.8 | 1 | -0.25 |
| Systemic Lupus Erythematosus | 1.3 | 1 | 0.3 |
| Tic Disorder | 0.2 | 1 | -4 |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 1.5 | 0.6 | 1.5 |
| Type 2 Diabetes | 2.2 | 2.7 | -0.23 |
| Ulcerative colitis | 0.3 | 2.6 | -7.67 |
| Unhealthy Ageing | 1.2 | 1.5 | -0.25 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.